日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study

在3b期SOLAR研究中，与比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺相比，卡博特韦+利匹韦林长效维持治疗12个月后，患者报告结局有所改善。

期刊:Aids and Behavior
影响因子:2.4
doi:10.1007/s10461-024-04490-0
Mussini, Cristina; Cazanave, Charles; Adachi, Eisuke; Eu, Beng; Alonso, Marta Montero; Crofoot, Gordon; Chounta, Vasiliki; Kolobova, Irina; Sutton, Kenneth; Sutherland-Phillips, Denise; Urbaityte, Rimgaile; Ehmann, Alice; Scherzer, Jenny; de Los Rios, Patricia; D'Amico, Ronald; Spreen, William; van Wyk, Jean
发表日期：2025
文献求助 收藏

Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide

长效卡博特韦和利匹韦林或比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺对体重和代谢的影响

期刊:Jaids-Journal of Acquired Immune Deficiency Syndromes
影响因子:2.2
doi:10.1097/QAI.0000000000003584
Tan, Darrell H S; Antinori, Andrea; Eu, Beng; Galindo Puerto, María José; Kinder, Clifford; Sweet, Donna; Van Dam, Cornelius N; Sutton, Kenneth; Sutherland-Phillips, Denise; Berni, Alessandro; Zhang, Feifan; Urbaityte, Rimgaile; Baugh, Bryan; Spreen, William; van Wyk, Jean; Garges, Harmony P; Patel, Parul; Batterham, Rachel; D'Amico, Ronald
代谢
发表日期：2025
文献求助 收藏

1550. Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women

1550. 通过优化新型实施策略，让黑人女性参与卡博特韦长效制剂暴露前预防（EBONI）研究：医护人员对卡博特韦长效制剂用于顺性别和跨性别黑人女性暴露前预防的适用性的看法

期刊:
影响因子:
doi:10.1007/s44202-022-00028-4
Alabdulla, Majid; Wadoo, Ovais; Iqbal, Yousaf; Chandrappa, Nirvana Swamy Kudlur; Chandra, Prem; Masoodi, Naseer Ahmed; Al-Maslamani, Muna A Rahman S; Latoo, Javed; Werner, Nicole; Richmond, Teriya; Dunn, Michael; Bernard, Marye; Urbaityte, Rimgaile; Sutton, Kenneth; Sutherland-Phillips, Denise; Dyson, Alftan; Merrill, Deanna; Chang, Samantha; Mack, Nicole; Haley, Amber; Brown, Kimberley; Evans, Tammeka
发表日期：2023
文献求助 收藏

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection

多替拉韦联合拉米夫定治疗HIV-1感染初治成人患者的抗逆转录病毒疗法三年持久疗效

期刊:AIDS
影响因子:3.1
doi:10.1097/QAD.0000000000003070
Cahn, Pedro; Sierra Madero, Juan; Arribas, José R; Antinori, Andrea; Ortiz, Roberto; Clarke, Amanda E; Hung, Chien-Ching; Rockstroh, Jürgen K; Girard, Pierre-Marie; Sievers, Jörg; Man, Choy Y; Urbaityte, Rimgaile; Brandon, Daisy J; Underwood, Mark; Pappa, Keith A; Curtis, Lloyd; Smith, Kimberly Y; Gartland, Martin; Aboud, Michael; van Wyk, Jean; Wynne, Brian
HIV
炎症/感染
微生物学
发表日期：2022
文献求助 收藏

1278. Real World Treatment Experience of Single Tablet Dolutegravir/Lamivudine in Those Naïve to Treatment with Baseline Viral Loads ≥ 100,000 copies/mL in the US

1278. 美国基线病毒载量≥100,000拷贝/毫升的初治患者使用单片多替拉韦/拉米夫定治疗的真实世界经验

期刊:Journal of Pharmaceutical Policy and Practice
影响因子:2.5
doi:10.1186/s40545-020-00262-y
Algunmeeyn, Abdullah; El-Dahiyat, Faris; Altakhineh, Mohammad Mitib; Azab, Mohammad; Babar, Zaheer-Ud-Din; Valenti, William M; Phoenix, John; Patel, Rupa R; Tims-Cook, Zandraetta; Pilgrim, Nanlesta; Haley, Amber; Sutton, Kenneth; Gaudion, Alison; Merrill, Deanna; Urbaityte, Rimgaile; Li, Bo; Andrae, David; Bonner, Courtney; Herbst, Abigail; Chowdhury, Dhuly; Garges, Harmony; Czarnogorski, Maggie; Benson, Paul; Donovan, Cindy; Harper, Gavin; Merrill, Deanna; Mycock, Katie L; Oglesby, Alan; Patarroyo, Jimena; Metzner, Aimee
微生物学
发表日期：2022
文献求助 收藏

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

多替拉韦联合拉米夫定治疗初治 HIV-1 感染成人患者的持久疗效：GEMINI-1 和 GEMINI-2 随机临床试验的 96 周结果

期刊:Jaids-Journal of Acquired Immune Deficiency Syndromes
影响因子:2.2
doi:10.1097/QAI.0000000000002275
Cahn, Pedro; Madero, Juan Sierra; Arribas, José R; Antinori, Andrea; Ortiz, Roberto; Clarke, Amanda E; Hung, Chien-Ching; Rockstroh, Jürgen K; Girard, Pierre-Marie; Sievers, Jörg; Man, Choy Y; Urbaityte, Rimgaile; Brandon, Daisy J; Underwood, Mark; Tenorio, Allan R; Pappa, Keith A; Wynne, Brian; Gartland, Martin; Aboud, Michael; van Wyk, Jean; Smith, Kimberly Y
HIV
GEMI
炎症/感染
微生物学
发表日期：2020
文献求助 收藏

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure

在将HLA-B*5701筛查作为风险缓解措施的十年间，阿巴卡韦超敏反应报告率

期刊:Pharmacotherapy
影响因子:3.4
doi:10.1002/phar.2196
Stainsby, Chris M; Perger, Teodora M; Vannappagari, Vani; Mounzer, Karam C; Hsu, Ricky K; Henegar, Cassidy E; Oyee, James; Urbaityte, Rimgaile; Lane, Charlotte E; Carter, Lindsay M; Pakes, Gary E; Shaefer, Mark S
发表日期：2019
文献求助 收藏

A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes

一项针对澳大利亚全科诊所的回顾性临床审计，旨在确定其改用多替拉韦/阿巴卡韦/拉米夫定方案的动机和临床结果。

期刊:International Journal of Std & Aids
影响因子:1.3
doi:10.1177/0956462417730474
Ferrer, Pedro E; Bloch, Mark; Roth, Norman; Finlayson, Robert; Baker, David; Koh, Ken; Orth, David; Urbaityte, Rimgaile; Brown, Dannae; Drummond, Fraser
发表日期：2018
文献求助 收藏